In a stratified survival analysis of ATG4B and pS383/392-ATG4B, there was increased risk of cancer death in CRC patients with early clinicopathological stages, such as AJCC stage I and II and no lymph node invasion (N0), whereas there were no significant effects in patients with well differentiated tumor cells and small tumor sizes (T1 and T2). This evidence concerns the gene ATG4B and cancer.